05:11 AM EDT, 08/01/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said late Thursday it completed patient enrollment in a phase 3 trial of GTX-102 for the treatment of Angelman syndrome, a neurogenetic disorder.

The trial, which enrolled 129 subjects, is expected to be completed in H2 2026.

The company said it expects to start a separate study of the drug in additional stages and genotypes in H2 2025.